Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Tuba Bas"'
Autor:
Jeffrey S. Weber, Dirk Schadendorf, Michele Del Vecchio, James Larkin, Victoria Atkinson, Michael Schenker, Jacopo Pigozzo, Helen Gogas, Stéphane Dalle, Nicolas Meyer, Paolo A. Ascierto, Shahneen Sandhu, Thomas Eigentler, Ralf Gutzmer, Jessica C. Hassel, Caroline Robert, Matteo S. Carlino, Anna Maria Di Giacomo, Marcus O. Butler, Eva Muñoz-Couselo, Michael P. Brown, Piotr Rutkowski, Andrew Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Luis de la Cruz-Merino, Andre van der Westhuizen, Alexander M. Menzies, Sandra Re, Tuba Bas, Veerle de Pril, Julia Braverman, Daniel J. Tenney, Hao Tang, Georgina V. Long
Publikováno v:
Scientia
PURPOSE Ipilimumab and nivolumab have each shown treatment benefit for high-risk resected melanoma. The phase III CheckMate 915 trial evaluated adjuvant nivolumab plus ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or IV mel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34fa1156641e9b8643e0a29aa14ae6a5
https://hdl.handle.net/11365/1232438
https://hdl.handle.net/11365/1232438
Autor:
Enriqueta Felip, Emilio Esteban, Ross Jennens, Helge Bischoff, Edward B. Garon, Jhanelle E. Gray, Nir Peled, Shirish M. Gadgeel, Giovanna Speranza, Steven Francis Powell, J. Yang, Delvys Rodriguez-Abreu, Rina Hui, Tuba Bas, Manuel Domine, Martin Reck, Silvia Novello, Maximilian Hochmair, Takayasu Kurata, Philip Clingan, Marina Chiara Garassino, M. Catherine Pietanza, Susanna Yee Shan Cheng, Belén Rubio-Viqueira, Michael Boyer, Francesco Grossi
Publikováno v:
Journal of Clinical Oncology. 38:1505-1517
PURPOSE In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo plus pemetrexed-platinum in patients with metastatic nonsquamous non‒sm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee3fac31820bd23cebc2d25b951fed70
https://doi.org/10.1200/jco.19.03136
https://doi.org/10.1200/jco.19.03136
Autor:
F.S. Hodi, Christopher D. Lao, Margarita Askelson, David A. Reardon, Omid Hamid, Kim Margolin, Anna C. Pavlick, M. S. Ernstoff, Reena Thomas, C-W. Lee, Nikhil I. Khushalani, Michael A. Postow, Michael B. Atkins, Alain Algazi, Caroline Chung, Karl D. Lewis, Tuba Bas, Peter A. Forsyth, Stergios J. Moschos, H.A. Tawbi
Publikováno v:
Annals of Oncology. 32:S871-S872
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0d438d09841e148fc65fb92618c9a44e
https://doi.org/10.1016/j.annonc.2021.08.1424
https://doi.org/10.1016/j.annonc.2021.08.1424
Autor:
Jerónimo Rodríguez-Cid, Ying Cheng, Irfan Cicin, Balazs Halmos, Sung Sook Lee, Barbara Hermes, David Vicente, Rodryg Ramlau, Bilal Piperdi, Ying Zhang, Tuba Bas, Hector Soto Parra, Luis Paz-Ares, Vladimir Vladimirov, Xuan Deng, Isamu Okamoto, Ali Tafreshi, Andrew G. Robinson, Julien Mazieres, Balazs Medgyasszay
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 15(10)
Introduction In the randomized KEYNOTE-407 study ( ClinicalTrials.gov , NCT02775435 ), pembrolizumab plus carboplatin and paclitaxel/nab-paclitaxel (chemotherapy) significantly improved overall survival (OS) and progression-free survival (PFS) compar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae4b12129de682a6061dc39d16386694
https://pubmed.ncbi.nlm.nih.gov/32599071
https://pubmed.ncbi.nlm.nih.gov/32599071
Autor:
Ivan Marquez-Rodas, V. Chiarion-Sileni, John Wagstaff, Dirk Schadendorf, James Larkin, Piotr Rutkowski, A. Hill, Jean-Jacques Grob, Tuba Bas, Wim van Dijck, John B. A. G. Haanen, Pier Francesco Ferrucci, C. Lance Cowey, Jedd D. Wolchok, Reinhard Dummer, Rene Gonzalez, F. Stephen Hodi, Christopher D. Lao, Michael Smylie, Marcus O. Butler
Publikováno v:
Annales de Dermatologie et de Vénéréologie - FMC. 1:A133
Introduction L’essai de phase 3 CheckMate 067 a montre un benefice clinique durable et prolonge avec l’association nivolumab (NIVO) + ipilimumab (IPI) et avec NIVO seul vs IPI sur une periode de suivi de 5 ans (taux de survie globale [SG] et de s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d47abbf579839c90fde60938f4a2a12
https://doi.org/10.1016/j.fander.2021.09.567
https://doi.org/10.1016/j.fander.2021.09.567
Autor:
Stéphane Dalle, Paolo A. Ascierto, Ralf Gutzmer, Jessica C. Hassel, Anna Maria Di Giacomo, Andrew Haydon, Marcus O. Butler, Jacopo Pigozzo, Tuba Bas, Piotr Rutkowski, Nicolas Meyer, Paola Queirolo, Victoria Atkinson, Shahneen Sandhu, Eva Muñoz-Couselo, Hao Tang, Matteo S. Carlino, James Larkin, Alexander M. Menzies, Daniel J. Tenney, Jeffrey S. Weber, Jean-Jacques Grob, Caroline Robert, Jacob Schachter, Thomas Eigentler, Sandra Re, Michael Schenker, Michele Del Vecchio, Dirk Schadendorf, Veerle de Pril, Georgina V. Long, Helen Gogas, Michael P. Brown
Publikováno v:
Cancer Research. 81:CT004-CT004
Background: NIVO has demonstrated significant benefit over IPI as adjuvant treatment in pts with resected stage IIIB–C or stage IV melanoma (AJCC v7). Combination NIVO + IPI has shown numerically longer survival than NIVO alone in pts with metastat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a63d6578edf7de479da8853f890c820
https://doi.org/10.1158/1538-7445.am2021-ct004
https://doi.org/10.1158/1538-7445.am2021-ct004
Autor:
Christopher D. Lao, Jean-Jacques Grob, Michael Smylie, Andrew G. Hill, Vanna Chiarion-Sileni, F. Stephen Hodi, James Larkin, Marcus O. Butler, Piotr Rutkowski, John B. A. G. Haanen, Tuba Bas, Charles Lance Cowey, Rene Gonzalez, John Wagstaff, Pier Francesco Ferrucci, Reinhard Dummer, Wim van Dijck, Dirk Schadendorf, Jedd D. Wolchok, Ivan Marquez-Rodas
Publikováno v:
Journal of Clinical Oncology. 39:9506-9506
9506 Background: In the phase 3 CheckMate 067 trial, a durable and sustained clinical benefit was achieved with nivolumab (NIVO) + ipilimumab (IPI) and NIVO alone vs IPI at 5-y of follow-up (overall survival [OS] and progression-free survival [PFS] r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20420a698d8153800a66185901742fd9
https://doi.org/10.1200/jco.2021.39.15_suppl.9506
https://doi.org/10.1200/jco.2021.39.15_suppl.9506
Autor:
Balazs Medgyasszay, X. Deng, Irfan Cicin, Andrew G. Robinson, Barbara Hermes, Julien Mazieres, Ali Tafreshi, Ying Cheng, Sung Sook Lee, J. Rodriguez Cid, Luis Paz-Ares, Tuba Bas, Rodryg Ramlau, H. Soto Parra, V. Vladimirov, David Vicente, Isamu Okamoto, Balazs Halmos, B. Beatrix, Bilal Piperdi
Publikováno v:
Annals of Oncology. 30:v918-v919
Background In the randomized KEYNOTE-407 study (NCT02775435), pembro + carboplatin and paclitaxel/nab-paclitaxel (chemo) significantly improved OS, PFS, and ORR compared with placebo + chemo in patients (pts) with previously untreated metastatic squa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c6bb39bca9cd29a1220201b9bb06371
https://doi.org/10.1093/annonc/mdz394.080
https://doi.org/10.1093/annonc/mdz394.080
Publikováno v:
Journal of Cellular Physiology. 230:1999-2005
Molecular dioxygen, O(2), is an important element in cellular microenvironment in vivo, and often overlooked in standard in vitro and ex vivo cell culture systems. Molecular oxygen is the ultimate electron acceptor in oxidative cellular respiration,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6872651a33630638dfed4c48c26b0d8
https://doi.org/10.1002/jcp.24953
https://doi.org/10.1002/jcp.24953
Autor:
Kshama D. Chandrasekhar, Anatoli Lvov, William R. Kobertz, Grace Y. Gao, Reid Gilmore, Tuba Bas
Publikováno v:
Journal of Biological Chemistry. 286:28150-28159
N-Glycosylation of membrane proteins is critical for their proper folding, co-assembly and subsequent matriculation through the secretory pathway. Here, we examine the kinetics of N-glycan addition to type I transmembrane KCNE1 K+ channel β-subunits
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::624ce8214175935f356e47b69c212f01
https://doi.org/10.1074/jbc.m111.235168
https://doi.org/10.1074/jbc.m111.235168